ArticleACS chemical neuroscience2021
Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils.
Article in ACS chemical neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Tau conformation, distribution and PET imaging correlations in progressive supranuclear palsy.Translational neurodegeneration · 2026Review
- Developing a novel reference region for [European journal of nuclear medicine and molecular imaging · 2025Article
- Structure-Activity Relationships and Evaluation of 2-(Heteroaryl-cycloalkyl)-1Journal of medicinal chemistry · 2025Article
- Efficient characterization of multiple binding sites of small molecule imaging ligands on amyloid-beta, tau and alpha-synuclein.European journal of nuclear medicine and molecular imaging · 2024Article
- Cryo-EM structures of pathogenic fibrils and their impact on neurodegenerative disease research.Neuron · 2024Review
- Tracing synaptic loss in Alzheimer's brain with SV2A PET-tracer UCB-J.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Insight into the Binding of First- and Second-Generation PET Tracers to 4R and 3R/4R Tau Protofibrils.ACS chemical neuroscience · 2023Article
- Review
- Tau positron emission tomography in patients with cognitive impairment and suspected Alzheimer's disease.Fukushima journal of medical science · 2023Article
- Head-to-Head Comparison of Tau-PET Radioligands for Imaging TDP-43 in Post-Mortem ALS Brain.Molecular imaging and biology · 2023Article
- Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy brains.Molecular psychiatry · 2023Article
- Evaluation of Tau Radiotracers in Chronic Traumatic Encephalopathy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Radiological assessment of dementia: the Italian inter-society consensus for a practical and clinically oriented guide to image acquisition, evaluation, and reporting.La Radiologia medica · 2022Article
- Molecular Imaging in Parkinsonian Disorders-What's New and Hot?Brain sciences · 2022Review
- Tau deposition patterns are associated with functional connectivity in primary tauopathies.Nature communications · 2022Article
- Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer's Disease and Other Tauopathies.Frontiers in aging neuroscience · 2022Review
- Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia.Frontiers in aging neuroscience · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease and primary tauopathies are characterized by the presence of tau pathology in brain. Several tau positron emission tomography (PET) tracers have been developed and studied in Alzheimer's disease (AD), but there is still a lack of 4R-tau specific tracers for non-AD tauopathies. We here present the first computational study on the binding profiles of four tau different PET tracers, PI2620, CBD2115, PM-PBB3, and MK6240, to corticobasal degeneration (CBD) tau. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.